Advances in the regulation of osteoclasts and osteoclast functions

Journal of Dental Research

Volumn 92, Issue 10, 2013, Pages 860-867

  Boyce, B F ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

apoptosis; bone biology; bone remodeling regeneration; chemokine(s); cytokine(s); osteoblast(s)

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL; APOPTOSIS; BONE BIOLOGY; BONE REMODELING; BONE REMODELING/REGENERATION; CELL COMMUNICATION; CELL SURVIVAL; CHEMOKINE(S); CYTOKINE(S); CYTOLOGY; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; OSTEOBLAST(S); OSTEOCLAST; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

APOPTOSIS; BONE BIOLOGY; BONE REMODELING/REGENERATION; CHEMOKINE(S); CYTOKINE(S); OSTEOBLAST(S);

ANIMALS; APOPTOSIS; BONE REMODELING; CELL COMMUNICATION; CELL SURVIVAL; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; OSTEOCLASTS; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 84884254939     PISSN: 00220345     EISSN: 15440591     Source Type: Journal    
DOI: 10.1177/0022034513500306     Document Type: Review

References (61)

1. Aarthi JJ, Darendeliler MA, Pushparaj PN. Dissecting the role of the S1P/S1PR axis in health and disease. J Dent Res. 2011 ; 90: 841-854
2. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone. 2007 ; 40: 251-264
3. Barrow AD, Raynal N, Andersen TL, Slatter DA, Bihan D, Pugh N, et al. OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest. 2011 ; 121: 3505-3516
4. Berthelot JM, Le Goff B. Rheumatoid arthritis and periodontal disease. Joint Bone Spine. 2010 ; 77: 537-541
5. Boonen S, Rosenberg E, Claessens F, Vanderschueren D, Papapoulos S. Inhibition of cathepsin K for treatment of osteoporosis. Curr Osteoporos Rep. 2012 ; 10: 73-79
6. Boyce BF. Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res. 2013 ; 28: 711-722
7. Boyce BF, Xing L. Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data. Clin Investig (Lond). 2011 ; 1: 1695-1706
8. Boyce BF, Yao Z, Xing L. Osteoclasts have multiple roles in bone in addition to bone resorption. Crit Rev Eukaryot Gene Expr. 2009 ; 19: 171-180
9. Boyce BF, Zuscik MJ, Xing L Thakker RV Eisman J Igarashi T Whyte MP, ed. London, UK: Elsevier ; 2012: 3-24.
10. Chen W, Zhu G, Hao L, Wu M, Ci H, Li YP. C/EBPalpha regulates osteoclast lineage commitment. Proc Natl Acad Sci USA. 2013 ; 110: 7294-7299
11. Crotti TN, Dharmapatni AA, Alias E, Zannettino AC, Smith MD, Haynes DR. The immunoreceptor tyrosine-based activation motif (ITAM) -related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. Arthritis Res Ther. 2012 ; 14: R245
12. Davy A, Soriano P. Ephrin signaling in vivo: look both ways. Dev Dyn. 2005 ; 232: 1-10
13. Del Fattore A, Cappariello A, Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone. 2008 ; 42: 19-29
14. Delgado-Calle J, Garmilla P, Riancho JA. Do epigenetic marks govern bone mass and homeostasis?. Curr Genomics. 2012 ; 13: 252-263
15. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev. 2012 ; 246: 379-400
16. Fujita K, Iwasaki M, Ochi H, Fukuda T, Ma C, Miyamoto T, et al. Vitamin E decreases bone mass by stimulating osteoclast fusion. Nat Med. 2012 ; 18: 589-594
17. Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012 ; 66: 1139-1146
18. Hemingway F, Taylor R, Knowles HJ, Athanasou NA. RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone. 2011 ; 48: 938-944
19. Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell. 2005 ; 8: 727-738
20. Hocking LJ, Whitehouse C, Helfrich MH. Autophagy: a new player in skeletal maintenance?. J Bone Miner Res. 2012 ; 27: 1439-1447
21. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 2003 ; 17: 2205-2232
22. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med. 2004 ; 10: 617-624
23. Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer. 2003 ; 97: 834S - 839S
24. Kalyan S, Quabius ES, Wiltfang J, Monig H, Kabelitz D. Can peripheral blood gammadelta T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug effects of aminobisphosphonate therapy. J Bone Miner Res. 2013 ; 28: 728-735
25. Kang S, Kumanogoh A. Semaphorins in bone development, homeostasis, and disease. Semin Cell Dev Biol. 2013 ; 24: 163-171
26. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008 ; 29: 155-192
27. Kikuta J, Iwai K, Saeki Y, Ishii M. S1P-targeted therapy for elderly rheumatoid arthritis patients with osteoporosis. Rheumatol Int. 2011 ; 31: 967-969
28. Kiviranta R, Yamana K, Saito H, Ho DK, Laine J, Tarkkonen K, et al. Coordinated transcriptional regulation of bone homeostasis by Ebf1 and Zfp521 in both mesenchymal and hematopoietic lineages. J Exp Med. 2013 ; 210: 969-985
29. Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, Nakashima K, et al. NFAT and Osterix cooperatively regulate bone formation. Nat Med. 2005 ; 11: 880-885
30. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J. 2008 ; 27: 535-545
31. Lotinun S, Kiviranta R, Matsubara T, Alzate JA, Neff L, Luth A, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest. 2013 ; 123: 666-681
32. Maeda K, Kobayashi Y, Udagawa N, Uehara S, Ishihara A, Mizoguchi T, et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med. 2012 ; 18: 405-412
33. Mahoney DJ, Swales C, Athanasou NA, Bombardieri M, Pitzalis C, Kliskey K, et al. TSG-6 inhibits osteoclast activity via an autocrine mechanism and is functionally synergistic with osteoprotegerin. Arthritis Rheum. 2011 ; 63: 1034-1043
34. Maruyama K, Fukasaka M, Vandenbon A, Saitoh T, Kawasaki T, Kondo T, et al. The transcription factor Jdp2 controls bone homeostasis and antibacterial immunity by regulating osteoclast and neutrophil differentiation. Immunity. 2012 ; 37: 1024-1036
35. Matsumoto T, Nagase Y, Iwasawa M, Yasui T, Masuda H, Kadono Y, et al. Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis. Arthritis Rheum. 2011 ; 63: 3908-3917
36. Mellis DJ, Itzstein C, Helfrich MH, Crockett JC. The skeleton: a multi-functional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption. J Endocrinol. 2011 ; 211: 131-143
37. Miller PD. A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis. 2011 ; 3: 271-282
38. Miyauchi Y, Ninomiya K, Miyamoto H, Sakamoto A, Iwasaki R, Hoshi H, et al. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med. 2010 ; 207: 751-762
39. Mori Y, Tsuji S, Inui M, Sakamoto Y, Endo S, Ito Y, et al. Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development. J Immunol. 2008 ; 181: 4742-4751
40. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007 ; 130: 811-823
41. Okamoto K, Takayanagi H. Regulation of bone by the adaptive immune system in arthritis. Arthritis Res Ther. 2011 ; 13: 219
42. Pacifici R. Role of T cells in ovariectomy induced bone loss - revisited. J Bone Miner Res. 2012 ; 27: 231-239
43. Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011 ; 49: 34-41
44. Ross FP, Teitelbaum SL. alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev. 2005 ; 208: 88-105
45. Schett G, David JP. The multiple faces of autoimmune-mediated bone loss. Nat Rev Endocrinol. 2010 ; 6: 698-706
46. Takayanagi H. New developments in osteoimmunology. Nat Rev Rheumatol. 2012 ; 8: 684-689
47. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002 ; 3: 889-901
48. Tanaka S, Miyazaki T, Fukuda A, Akiyama T, Kadono Y, Wakeyama H, et al. Molecular mechanism of the life and death of the osteoclast. Ann NY Acad Sci. 2006 ; 1068: 180-186
49. Tanaka S, Wakeyama H, Akiyama T, Takahashi K, Amano H, Nakayama KI, et al. Regulation of osteoclast apoptosis by Bcl-2 family protein Bim and Caspase-3. Adv Exp Med Biol. 2010 ; 658: 111-116
50. Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009 ; 15: 757-765
51. Teitelbaum SL. The osteoclast and its unique cytoskeleton. Ann NY Acad Sci. 2011 ; 1240: 14-17
52. Vaira S, Alhawagri M, Anwisye I, Kitaura H, Faccio R, Novack DV. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest. 2008 ; 118: 2088-2097
53. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006 ; 12: 17-25
54. Wang Z, McCauley LK. Osteoclasts and odontoclasts: signaling pathways to development and disease. Oral Dis. 2011 ; 17: 129-142
55. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002 ; 347: 175-184
56. Xiong J, O'Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res. 2012 ; 27: 499-505
57. Yagi M, Ninomiya K, Fujita N, Suzuki T, Iwasaki R, Morita K, et al. Induction of DC-STAMP by alternative activation and downstream signaling mechanisms. J Bone Miner Res. 2007 ; 22: 992-1001
58. Yao Z, Xing L, Boyce BF. NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J Clin Invest. 2009 ; 119: 3024-3034
59. Yasui T, Hirose J, Tsutsumi S, Nakamura K, Aburatani H, Tanaka S. Epigenetic regulation of osteoclast differentiation: possible involvement of Jmjd3 in the histone demethylation of Nfatc1. J Bone Miner Res. 2011 ; 26: 2665-2671
60. Zhao B, Ivashkiv LB. Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors. Arthritis Res Ther. 2011 ; 13: 234
61. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006 ; 4: 111-121